Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David E Cohn

Showing results (1-10 of 301) with videos related to

Pageof 31
Sort By:
Gynecologic Oncology|March 24, 2023
"The times they are a-changin'" - And how are we managing?David E Cohn
Gynecologic Oncology|August 9, 2011
What does cost have to do with it?David E Cohn
Journal of Gynecologic Oncology|April 25, 2014
Surgery or chemoradiation for stage IB cervical cancer? How cost effectiveness impacts a complex decisionDavid E Cohn
Adolescent Medicine Clinics|January 1, 2005
Gynecologic malignancies in adolescentsMarshall Stepanian, David E Cohn
Gynecologic Oncology|March 21, 2017
Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?Thomas J Herzog, David E Cohn
Gynecologic Oncology Reports|October 2, 2015
The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?David E Cohn, William S Shimp
Gynecologic Oncology|January 15, 2018
Cancer care delivery research in gynecologic oncologyDavid I Shalowitz, David E Cohn
Clinical Obstetrics and Gynecology|April 22, 2011
Lynch syndromeFloor J Backes, David E Cohn
Gynecologic Oncology|December 14, 2004
Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupRussell J Schilder, John Blessing, David E Cohn
Gynecologic Oncology|August 3, 2018
Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancerKian Behbakht, David E Cohn, J Michael Straughn
Pageof 31

Showing results (1-10 of 301) with videos related to

Sort By:
Pageof 31
Gynecologic Oncology|March 24, 2023
"The times they are a-changin'" - And how are we managing?David E Cohn
Gynecologic Oncology|August 9, 2011
What does cost have to do with it?David E Cohn
Journal of Gynecologic Oncology|April 25, 2014
Surgery or chemoradiation for stage IB cervical cancer? How cost effectiveness impacts a complex decisionDavid E Cohn
Adolescent Medicine Clinics|January 1, 2005
Gynecologic malignancies in adolescentsMarshall Stepanian, David E Cohn
Gynecologic Oncology|March 21, 2017
Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?Thomas J Herzog, David E Cohn
Gynecologic Oncology Reports|October 2, 2015
The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?David E Cohn, William S Shimp
Gynecologic Oncology|January 15, 2018
Cancer care delivery research in gynecologic oncologyDavid I Shalowitz, David E Cohn
Clinical Obstetrics and Gynecology|April 22, 2011
Lynch syndromeFloor J Backes, David E Cohn
Gynecologic Oncology|December 14, 2004
Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology GroupRussell J Schilder, John Blessing, David E Cohn
Gynecologic Oncology|August 3, 2018
Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancerKian Behbakht, David E Cohn, J Michael Straughn
Pageof 31